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Research Question: 45 
What is the difference of endometrial transcriptomics between women with normal and low mid-luteal 46 
progesterone during the implantation window?  47 
Design: 48 
An endometrial biopsy and serum progesterone level were taken from participants during the mid-luteal 49 
phase (LH+7 to LH+9). A total of 12 participants were recruited. The participants were categorised into 50 
two groups based on their progesterone levels: normal progesterone (>15 ng/ml, n=6) and low 51 
progesterone (<15 ng/ml, n=6). Global endometrial gene expression between the two groups was 52 
compared by microarray techniques. Principal component analysis (PCA) was used to display the 53 
gene’s expression pattern. Pathway and gene ontology enrichment analysis were performed to 54 
determine the biological mechanism of progesterone on the endometrium. 55 
Results: 56 
Several key genes related to endometrial receptivity were found to be regulated by progesterone. With 57 
regard to gene ontology and pathway analysis, progesterone was shown to be mainly involved in 58 
structure morphogenesis predominantly during a process of decidualisation, extracellular matrix-59 
receptor interaction, and cell adhesion. Distinct differences in the transcriptomic profiles between the 60 
two groups were observed indicating potential impairment of endometrial receptivity in women with 61 
suboptimal progesterone levels. There was a relatively similar pattern of gene expression between 62 
endometrial samples with progesterone levels approximately 10 ng/ml and >15 ng/ml. Thus, a 63 
progesterone level of between 10-15 ng/ml seems to be sufficient to induce endometrial receptivity.  64 
Conclusions: 65 
Abnormally low progesterone below the threshold of 10-15 ng/ml during the implantation window 66 
results in aberrant endometrial gene expression that may affect implantation potential.  67 
Trial registration:  68 
This trial was registered at clinicaltrials.gov as NCT04323683  69 
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The human endometrium undergoes cyclical changes in response to fluctuations in steroid hormone 73 
levels during the menstrual cycle. It is essential that the endometrium reaches a receptive stage initiating 74 
embryo-endometrial dialogue which results in invasion, placentation, fetal development, and finally 75 
parturition (Finn and Martin, 1974, Paria et al., 2002). The time that the endometrium becomes receptive 76 
is the window of implantation (WOI) taking place around day 21 of a 28-day menstrual cycle or 77 
approximately 7 days following the LH surge (Navot et al., 1991, Prapas et al., 1998, Riesewijk et al., 78 
2003). During this period, the endometrial environment is conducive to blastocyst implantation.  79 
Progesterone is a major contributing factor in transforming the non-receptive to the receptive 80 
endometrium. Progesterone concentration physiologically peaks at the mid-luteal phase corresponding 81 
to the window of implantation (Reed and Carr, 2015). Progesterone inhibits the proliferative effect of 82 
oestrogen on uterine epithelial cells and induces endometrial receptivity by promoting stromal cell 83 
proliferation/differentiation and decidual growth. Furthermore, it is involved in the regulation of 84 
expression of key cell adhesion molecules, growth factors, and cytokines essential for embryo 85 
implantation (Okada et al., 2018).  86 
Endometrial transcriptomics has been shown to be regulated by cyclical hormonal change (Ruiz-Alonso 87 
et al., 2012, Haouzi et al., 2012, Mirkin et al., 2005, Díaz-Gimeno et al., 2011). A whole genome 88 
association study has yielded insights into endometrial transcriptomic changes during the natural cycle 89 
(Talbi et al., 2006) supporting the concept of a receptive gene expression profile (Garrido-Gómez et al., 90 
2013, Bhagwat et al., 2013, Díaz-Gimeno et al., 2011). Suboptimal progesterone level is involved in 91 
delayed endometrial maturation and abnormal patterns of gene expression (Young et al., 2017) resulting 92 
in implantation failure, therefore sufficient progesterone concentration appear to be important for 93 
successful implantation. 94 
It is hypothesised that women with suboptimal progesterone levels result in a non-receptive 95 
endometrium as this steroid is responsible for endometrial preparation to achieve implantation. 96 
Compromised pregnancy rates have been shown when mid-luteal progesterone levels are lower than 97 
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the threshold of 10-15 ng/ml in a natural cycle (Jordan et al., 1994, Radwanska et al., 1981, Hull et al., 98 
1982). The gene expression pattern between women with normal and women with low progesterone 99 
will be compared in this study. If aberrant gene expression is found in the lower progesterone group 100 
compared with the normal group, it would suggest the importance of having sufficient progesterone 101 
levels during the mid-luteal phase. We further investigated the key genes associated with implantation 102 
and pathways regulated by progesterone for a better understanding of progesterone activities. This is 103 
the first study aiming to clarify the effect of low versus normal progesterone on gene expression profile 104 
during the human mid-luteal phase. 105 
Objectives  106 
Primary objective 107 
To determine the relationship of mid-luteal serum progesterone and endometrial gene expression by 108 
comparing endometrial transcriptomics in women with low progesterone versus women with normal 109 
progesterone during the implantation window.  110 
Secondary objective 111 
To investigate genes associated with implantation, gene ontology, and pathway analysis regulated 112 




Participant characteristics  115 
This study was approved by the Nottingham Research Ethics Committee, United Kingdom (NRES 116 
reference: 13/EM/0277). This study was conducted at the Nottingham University Research and 117 
Treatment Unit in Reproduction (Nurture), Nottingham, UK. Written informed consent was obtained 118 
from all participants in accordance with the guidelines in The Declaration of Helsinki. Women who met 119 
the following criteria were recruited: aged 18-35 years, regular menstrual cycles with an interval of 25-120 
35 days, a body mass index (BMI) between 18 – 25, no history of taking hormonal medication in the 121 
last 3 months. Based on progesterone concentration on the day of endometrial biopsy (LH+7 to LH+9), 122 
participants were categorised into two groups based on normal progesterone (≥ 15 ng/ml) and low 123 
progesterone levels (< 15 ng/ml).  A total of 12 endometrial samples were selected based on 124 
progesterone levels to proceed with microarray analysis. 125 
Study protocol 126 
Participants were asked to use barrier methods of contraception or abstain from sexual intercourse. 127 
Urinary luteinising hormone (LH) kit (Ovuquik One Step; Quidel, SanDiego, CA, USA) was given to 128 
detect the LH surge beginning on day 10 of the natural cycle, the day of the urinary LH surge was 129 
considered to be LH=0. Women with positive LH test denoting ovulation were arranged to undergo an 130 
endometrial biopsy on day LH+7 to LH+9 of the menstrual cycle. A pregnancy test was performed prior 131 
to endometrial biopsy. Women who had a negative pregnancy test were eligible to undergo biopsy. An 132 
endometrial biopsy was obtained using Pipelle de Cornier endometrial sampler (CCD, Paris). The 133 
device was introduced into the uterus until resistance from the fundus was felt. Negative pressure was 134 
generated and the device rotated through 360° as it was gradually withdrawn. An endometrial biopsy 135 
was undertaken from all four walls of the endometrial cavity under aseptic conditions. Endometrial 136 
samples were frozen in liquid nitrogen and stored at -80°C. Blood samples for progesterone were 137 





Blood sample analysis 141 
Blood sampling was undertaken in accordance with a standard phlebotomy protocol in the morning 142 
(8.00-10.00 AM). The blood tube was centrifuged (4000 rpm for 20 minutes), and the supernatant was 143 
used for analysis. Serum progesterone concentrations were measured using automated electro 144 
chemiluminescent immunoassays (Abbott Diagnostics, UK). The measurement was performed 145 
according to manufacturer’s instructions using a commercially available chemiluminescent 146 
immunoassay kit. The progesterone assay had a sensitivity of ≤ 0.1 ng/ml. The intra-assay coefficient 147 
of variation was 2.9 % and the inter-assay coefficient of variation was 3.5 %. 148 
 149 
RNA extraction and quality control 150 
Total RNA was extracted from the endometrium samples by using the RNeasy Mini Kit (QIAGEN) 151 
according to the manufacturer’s instructions. The RNA concentration was measured using the 152 
Nanodrop RNA quantification. Sample concentration and purity were determined by 153 
spectrophotometry, and RNA integrity was confirmed using an Agilent 2100 Bioanalyzer with the RNA 154 
6000 Nano Kit (Agilent Technologies). Only samples surpassing the minimal quality threshold (RIN > 155 
8.0) were used in the subsequent transcriptomic assessment. 156 
Transcriptome profiling with Affymetrix GeneChip  157 
cDNA was prepared from 200ng of RNA as per the GeneChip WT-PLUS Reagents Kit (Affymetrix),  158 
followed by in vitro transcription to produce cRNA, end-labelled and hybridized for 16 hours at 45°C 159 
to Clariom S array Human (Affymetrix). All steps were performed by Gene Chip Fluidics Station 450 160 
(Affymetrix) according to the manufacturer's instructions. Detection was performed using a GeneChip 161 
Scanner 3000 7G (Affymetrix). 162 
Expression array analysis  163 
Whole transcriptome analysis was performed to compare the gene expression profile between the 164 
normal progesterone group (n=6) and the low progesterone group (n=6). Gene expression data were 165 
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analysed using Partek Genomics Suite 6.6 software (Partek). The raw CEL files were normalized using 166 
the robust multiarray average (RMA) background correction with quantile normalization, log base 2 167 
transformation and mean probe-set summarization with adjustment for guanine-cytosine content. 168 
Differentially expressed genes were considered significant if P-value was ≤ 0.05 at a fold change (FC) 169 
of 1.5 with false-discovery rate (FDR) < 0.05. Principal component analysis (PCA) was used to analyse 170 
large amounts of the dataset from the microarray. It displays a multidimensional dataset in three 171 
dimensions allowing clear visualisation of the gene’s expression pattern. Hierarchical clustering was 172 
used to create clusters that have a predetermined ordering from top to bottom to differentiate gene 173 
pattern expression among different groups. Enrichment analyses for Gene Ontology (GO) terms and 174 
biological pathways (KEGG) were carried out by using the g: Profiler web tool 175 
(https://biit.cs.ut.ee/gprofiler/gost ) (Raudvere et al., 2019). A P-value of less than 0.05 was considered 176 
significant. Gene expression profiles have been deposited in the National Center for Biotechnology 177 
Information Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series 178 
accession number GSE143620.  179 
 180 
Microarray Validation by RT-PCR 181 
Microarray validation was carried out by reverse transcriptase-polymerase chain reaction (RT-PCR) in 182 
samples from both groups. The RT-PCR was performed for eight selected differentially expressed 183 
genes: CXCL13, DKK1, SPP1, IL15, MMP10, ND6, MMP3, and TRH.  184 
 185 
PCR was performed in a total volume containing 1.5 μL of cDNA; 0.75 μL of TaqMan Assays: 186 
CXCL13 (Hs00757930_m1), SPP1 (Hs00959010_m1), DKK1 (Hs00183740_m1), IL15 187 
(Hs01003716_m1); 7.5 μL TaqMan fast universal master mix; and 5.25 μL H20. All reactions were run 188 
in triplicate. Real-time PCR was run on the ABI 7500 fast real-time PCR system. The reaction 189 
underwent a heating step at 95°C for 20 minutes and then cycled 40 times at 95°C for 3 seconds followed 190 
by 60°C for 30 seconds. 18S mRNA expression was used for data normalisation. Student’s t-test was 191 
performed with Statistical Package for the Social Sciences (SPSS) Statistics 26. A p-value < 0.05 was 192 




Baseline characteristics 195 
There was no significant difference observed in age, cycle length, and BMI between the two groups. 196 
All participants were caucasian and non-smokers. Progesterone levels were statistically different 197 
between the two groups (Table 1, Figure 1). The annotation of baseline characteristics for each single 198 
microarray data is provided in Supplementary 1. 199 
 200 
The pattern of gene expression 201 
Principal component analyses (PCA) reveals a clear distinction in the pattern of gene expression 202 
between the normal and low progesterone groups (Figure 2). The pattern of gene expression of each 203 
woman with normal progesterone displays similarly, whereas the gene expression of the women with 204 
low progesterone scattered based on progesterone levels. In the low progesterone group, samples with 205 
the lowest progesterone levels of 3.51 and 4.22 ng/ml displayed their position farthest from the normal 206 
progesterone group on the left side ((principal component 1 (PC1): principal component 2 (PC2) = (-207 
260, -10) and (-234, 31)). Two samples with progesterone levels of 4.41, 5.78 ng/ml exist below the 208 
normal group ((PC1:PC2) = (24, -101) and (32, -113)). The pattern of endometrial transcriptomics of 209 
samples with progesterone levels of 9.5, 9.8 ng/ml ((PC1:PC2) = (67, 53) and (76, 64)) was comparable 210 
to the normal progesterone group having progesterone levels of 15.5, 16, 17.2, 18.17, 20.37, and 28.61 211 
ng/ml (Figure 2). 212 
Differentially expressed genes, gene ontology and pathway analysis 213 
Global gene expression profiles were analysed by microarray technology comparing the endometrial 214 
expression patterns of participants with low progesterone versus normal progesterone at the threshold 215 
of 15 ng/ml. A total of 1279 genes displayed a >1.5-fold significant change in expression between the 216 
two groups. 805 genes were down-regulated and 474 genes were up-regulated in the low progesterone 217 
group compared with the normal group (Supplementary 2).  218 
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Gene ontology and pathway analysis were carried out to identify critical progesterone activities on the 219 
endometrium during the receptive phase. Enrichment analysis is arranged according to biological 220 
processes, molecular functions and cellular components (Figure 3A, 3B, and 3C). The enriched 221 
biological processes were mainly involved in anatomical structure morphogenesis, tissue development, 222 
cell adhesion and biological adhesion (Figure 3A). With respect to molecular function, differentially 223 
expressed genes were mainly associated with glycosaminoglycan binding, extracellular matrix 224 
structural constituent, sulfur compound binding, ion binding, and heparin binding (Figure 2B). For 225 
cellular component annotation classification, significant genes were mainly localized in the 226 
extracellular matrix, endomembrane system, collagen-containing extracellular matrix, endoplasmic 227 
reticulum and cytoplasm (Figure 3C). Full lists of genes were provided in Supplementary 3.  228 
 229 
Pathway analysis of the differentially expressed genes was carried out using the Kyoto Encyclopedia 230 
of Genes and Genomes (KEGG). Enriched KEGG pathways are shown in Figure 3D. Among these 231 
differentially regulated pathways, ECM-receptor interaction, focal adhesion, and PI3K-Akt signalling 232 
pathway were the most enriched pathways. Extracellular matrix and adhesion appear to be dominant in 233 
both pathway and gene ontology analysis. Full lists of genes were provided in Supplementary 3. 234 
Differentially expressed genes associated with decidualisation and implantation  235 
 236 
The functional analysis in our study shows that 254 genes (Supplementary 2) are associated with 237 
anatomical structure morphogenesis which is characteristic of the decidualisation process (Okada et al., 238 
2018). An in vitro cell culture model by Lucas et al. showed 898 differentially expressed 239 
decidualisation-associated genes between undifferentiated endometrial stromal cells and the cells 240 
exposed to progesterone for two days (Lucas et al., 2020). A total of 33 overlapping genes were 241 
extracted indicating highly potential genes regulating the process of decidualisation (Figure 4A, 242 




Endometrial receptivity-related genes that regulated by progesterone were examined by comparing the 245 
genes identified by our study with the previous evidence reporting gene associated endometrial 246 
receptivity, we found 11% of the 238 ERA genes (27/238) (Díaz-Gimeno et al., 2011) and 14% of the 247 
57 genes in the meta-analysis of genes-related endometrial receptivity (9/57) by Altmäe et al. (Altmäe 248 
et al., 2017) were differentially expressed between the low and normal progesterone groups (Table 2, 249 
Figure 4B). Pathway analysis revealed that those 27 overlapping genes with ERA were associated with 250 
mineral absorption (Figure 5, Supplementary 4).  Seven genes were present in all three studies: SPP1, 251 
IL15, DKK1, CLDN4, BCL6, MT1H, and MT1G. Progesterone-dependent genes that are over-252 
representative during implantation window are also potential genes involved in the process of 253 
implantation.  We compared our gene list with a study by  Chi et al. that reported 653 differentially 254 
expressed genes with altered progesterone receptor (PGR) binding between proliferative and mid-luteal 255 
phase (Chi et al., 2020) and study by Young et al. that showed 182 differentially expressed genes 256 
between women receiving adequate and inadequate progesterone supplementation during the luteal 257 
phase (Young et al., 2017)(Figure 4C). Seven overlapping genes were found among three studies: CILP, 258 
CRYAB, CYP4B1, DKK1, KLF4, MAMDC2, and SLIT3. Full lists of genes were provided in 259 
Supplementary 2.  260 
 261 
Bar charts were generated to present the directionality between this study and other studies. The fold 262 
change was adjusted to make comparable to this study, the original fold change was multiply by -1. It 263 
was found that the majority of the overlapping genes were up- or down-regulated in the same direction 264 
between our study and four other studies for all comparisons (Figure 6): 66% ERA (18/27 genes) (Díaz-265 
Gimeno et al., 2011), 82% Lucus et al. (27/33 genes) (Lucas et al., 2020), 87% Chi et al. (103/118 266 
genes) (Chi et al., 2020), 100% Young et al. (21/21 genes) (Young et al., 2017). A total of 21/37 267 
overlapping genes were analysed between our study and young et al. as fold changes of some genes 268 
were not provided in the original publication. 269 
 270 
Subgroup analysis 271 
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According to PCA result, the gene expression pattern of samples with progesterone levels of 272 
approximately 10 ng/ml had a relatively similar expression to samples with progesterone levels of  ≥15 273 
ng/ml, thus we further performed subgroup analysis by comparing  gene expression profile between 274 
normal progesterone group and the group with progesterone levels of approximately 10 ng/ml (the first 275 
low progesterone subgroup); and between normal progesterone group and the group with lower 276 
progesterone levels of  3-6 ng/ml (the second low progesterone subgroup). Only 8 differentially 277 
expressed genes were found in the comparison between normal progesterone group and the first low 278 
progesterone subgroup, whereas 1309 genes were differentially expressed between normal progesterone 279 
group and the second low progesterone subgroup. The hierarchical clustering of both comparisons was 280 
shown in Figures 7A and 7B. According to pathway analysis, no pathway involved in implantation was 281 
significantly enriched between normal progesterone group and the first low progesterone subgroup 282 
(Figure 8, Supplementary 5) whereas the pathways involved with ECM-receptor interaction, focal 283 
adhesion, mineral absorption were significantly enriched between normal progesterone group and the 284 
second lower progesterone subgroup (Figure 9, Supplementary 6).  285 
 286 
Microarray Validation by RT-PCR 287 
RT–PCR was used to verify mRNA expression levels indicated by microarray analysis. Eight genes 288 
were selected for this purpose. According to Figure 10, four genes were significantly up-regulated, and 289 
four genes were significantly down-regulated, which is consistent with the microarray results (P < 0.05 290 
for all comparisons between low and normal progesterone group)  291 
Discussion 292 
This is the first study comparing the transcriptomic profile of the endometrium in women with normal 293 
mid-luteal progesterone versus women with low mid-luteal progesterone during the receptive phase of 294 
the natural cycle. Distinct differences in the transcriptomic profiles between women with low and 295 
normal progesterone at the threshold of 15 ng/ml were observed indicating potential impairment of 296 
endometrial receptivity in women with suboptimal progesterone levels. There was a relatively similar 297 
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pattern of gene expression between endometrial samples with progesterone levels approximately 10 298 
ng/ml and >15 ng/ml. Thus, a progesterone concentration of between 10-15 ng/ml appears to be 299 
sufficient to induce endometrial receptivity. In this study, participants in both groups had regular cycle 300 
approximately 28 days suggesting the progesterone levels in this study tends to be measured in an 301 
ovulated cycle, although some women had low progesterone levels (Table 1). 302 
  303 
A difference in transcriptomic patterns between the two groups according to the PCA plot was observed 304 
suggesting that abnormally low progesterone may induce inappropriate endometrial transcriptomic 305 
profiles in which may result in implantation failure. Once the progesterone level was higher than the 306 
threshold of 15 ng/ml the pattern of endometrial expression of all samples in normal progesterone group 307 
becomes relatively similar to each other, however, the pattern of endometrial transcriptomics at 9.5 and 308 
9.8 ng/ml is comparable to that observed in the normal progesterone group. Subgroup analysis with 309 
hierarchical clustering revealed that a large number of genes were differentially expressed between 310 
samples with normal progesterone and samples with very low progesterone (3-6 ng/ml), whereas only 311 
8 differentially expressed genes were found in the comparison between samples with normal 312 
progesterone and samples with progesterone levels  ≈ 10 ng/ml. It would suggest that aberrant 313 
endometrial gene expression is caused by suboptimal progesterone levels and mid-luteal progesterone 314 
of approximately 10 ng/ml appears to be adequate for successful implantation. There was no significant 315 
enriched biological process, molecular functions, and cellular component between normal progesterone 316 
group and group with progesterone levels of approximately 10 ng/ml. The pathway involved in 317 
implantation was also not significantly enriched between the two groups suggesting a relatively similar 318 
effect on the endometrium between the two groups. A pathway involved in ECM-receptor interaction 319 
and focal adhesion should be highlighted as progesterone-related pathways, as they were significantly 320 
enriched in both main analysis and subgroup analysis between normal progesterone group and the group 321 
with progesterone levels of 3-6 ng/ml. 322 
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A cut-off value of mid-luteal progesterone remains uncertain due to limited evidence. The threshold 323 
of 15 ng/ml was taken from a study by Basnayake et al. (2018) that reported compromised pregnancy 324 
rate in women with mid-luteal progesterone lower than 15.7 ng/ml (Basnayake et al., 2018). Although 325 
it is a large study recruiting a total of 4582 participants, we acknowledge that the reliability of the 326 
exact threshold for a natural cycle is limited due to inclusion of women undergoing both natural and 327 
artificial frozen-thawed embryo transfer cycles. However, Hull et al. (1982) showed a mid-luteal 328 
progesterone threshold of approximately 10 ng/ml in pregnant patients following unstimulated cycles 329 
(Hull et al., 1982). Due to the uncertainty of the mid-luteal progesterone threshold, subgroup analysis 330 
will provide more detail for transcriptomic analysis.  In this study, progesterone samples were taken in 331 
the morning, according to clinical practice, when concentrations have been reported to reached a peak 332 
(Filicori et al., 1984, Syrop and Hammond, 1987). Therefore, we considered that the threshold of 10 333 
ng/ml and the higher cut-off value of 15 ng/ml is reasonable to carry out the differential gene 334 
expression analysis. 335 
 336 
After comparison our gene list to other studies, we found differentially expressed genes that are strongly 337 
associated with decidualisation and implantation.  Our result suggests that SPP1, IL15, DKK1, CLDN4, 338 
BCL6, MT1H, and MT1G are endometrial receptivity-related genes that were regulated under the 339 
progesterone effect. CILP, CRYAB, CYP4B1, DKK1, KLF4, MAMDC2, and SLIT3 are progesterone-340 
dependent genes that typically over-representative during the implantation window. Noticeably, DKK1 341 
was present in both two comparisons and also a decidualisation-related gene (Lucas et al., 2020) 342 
highlighting the importance of DKK1 during implantation. DKK1 is normally upregulated during the 343 
implantation window (Díaz-Gimeno et al., 2011), low progesterone group in our study allows 344 
significantly downregulation of DKK1 expression possibly resulting in a negative effect on 345 
implantation. CXCL13, which is the most highly expressed gene in this study, it is progesterone-346 
dependent genes (Young et al., 2017) and also involved in endometrial receptivity (Díaz-Gimeno et al., 347 
2011). CXCL13 is associated with regulation of immune response (Hannan and Salamonsen, 2007, 348 
Salamonsen et al., 2007) and tissue invasion (Franasiak et al., 2015, Dominguez et al., 2008). The 349 
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expression of CXCL13 was significantly down-regulated in women with implantation failure in 350 
comparison to controls (Li et al., 2017). CXCL13 is also down-regulated in the low progesterone group 351 
in our study suggesting the potential impairment of endometrial receptivity in this group.  352 
 353 
Our results showed that optimal endometrial transcriptomics is achieved under a sufficient amount of 354 
progesterone. One-fourth of recurrent implantation failure (RIF) is caused by the displacement of the 355 
window of implantation, plausibly resulting from suboptimal progesterone levels (Ruiz-Alonso et al., 356 
2013). The endometrial biopsy was obtained to perform the ERA test on the receptive period of cycle 357 
(day LH+7 in a natural cycle or day P+5 in an artificial cycle) and the results were grouped into pre-358 
receptive, receptive and post-receptive (Díaz-Gimeno et al., 2013). Based on the ERA test that showed 359 
non-receptive results, it is divided into pre-receptive (85.0%) or post-receptive (12.6%) for endometrial 360 
tissue assessed during the receptive phase (Katzorke et al., 2016). It has been shown that a suboptimal 361 
progesterone level is associated with delayed endometrial maturation and abnormal patterns of gene 362 
expression (Young et al., 2017). On the other hand, excess progesterone results in the advancement of 363 
endometrial maturation (Van Vaerenbergh et al., 2011). Consequently, abnormally low progesterone 364 
levels inadequate to achieve the receptive stage of endometrium would be expressed as a pre-receptive 365 
stage which is the majority of the non-receptive group and excess progesterone could result in post-366 
receptive expression. The personalised embryo transfer according to the ERA result has a potential to 367 
improve pregnancy rates in women with RIF who have non-receptive results  (Hashimoto et al., 2017, 368 
Ruiz-Alonso et al., 2013), suggesting the receptive state of endometrium could be achieved by 369 
abnormally low or high progesterone however the timing of implantation is delayed or advanced. 370 
Collectively, abnormal progesterone levels are associated with the displacement of the window of 371 
implantation, therefore embryo transfer typically performed at the presumed receptive phase will not 372 
be successful.  Progesterone monitoring appears to be useful and it might also integrate with a genomic 373 
diagnostic tool to assess endometrial receptivity in the future. However, there was a lack of evidence 374 
for a certain level of upper limit of progesterone concentration during the mid-luteal phase. Too high 375 
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progesterone levels could have a detrimental effect on endometrial receptivity, further study is required 376 
to figure out the upper limit of progesterone level during the receptive period of menstrual cycle. 377 
 378 
Variation in progesterone production could be expected among different menstrual cycles of the same 379 
woman and among different women. Intercycle variation (within-women) is considerably lower than 380 
interindividual variation as intercycle variance accounted for approximately 20-30% of the total 381 
variance (intercycle variation and interindividual variation) in luteal phase progesterone (Lenton et al., 382 
1983, Sukalich, 1994, Gann et al., 2001). Due to low intercycle variation, progesterone measurement 383 
is highly predictable and reproducible between cycles (Chatterton et al., 2005). With regard to the 384 
daytime variation in a cycle, we acknowledge the limitation in our study and the single point 385 
progesterone measurement as it was previously reported that progesterone is secreted in pulses and 386 
fluctuate depending on LH pulsatile release over the course of a day, with highest concentrations in 387 
the morning (0800-1000hrs) with little fluctuation thereafter (Filicori et al., 1984); (Syrop and 388 
Hammond, 1987). The authors also conclude that the effect of clinically significant fluctuations is 389 
minimised by the use of timed sampling (Syrop and Hammond, 1987). In this work, we limit the mid-390 
luteal progesterone timed sampling to 8.00 -10.00 AM to minimise the variation and to allow a 391 
reasonable comparison between the 12 samples reported. 392 
 393 
Our results suggest that the cut-off value of mid-luteal progesterone at the threshold of 15 ng/ml, could 394 
be lowered to 10 ng/ml in the natural cycle. Frozen-thawed embryo transfer could be performed in either 395 
a natural cycle or artificial hormonally-controlled cycles. It is challenging whether this threshold is 396 
acceptable in an artificial cycle. In the artificial cycle, exogenous oestrogen inhibits ovulation and 397 
progesterone supplementation is given to replace progesterone physiologically produced by the corpus 398 
luteum in the natural cycle.  The recent and largest retrospective study in 2018  (Basnayake et al., 2018) 399 
recruiting a total of 4582 participants undergoing either artificial or natural frozen-thawed embryo 400 
transfer cycles proposed the cut-off value at 15.7 ng/ml and another prospective study by Labarta et al., 401 
which recruited only artificial cycle, showed the thresholds at 9.2 ng/ml (Labarta et al., 2017). The most 402 
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recent retrospective study in 2019 also showed improved pregnancy rates in women who have a 403 
relatively similar progesterone level to the previous study at 10 ng/ml  (Cédrin-Durnerin et al., 2019). 404 
Those studies demonstrated comparable results with our study ranging from approximately 10-15 405 
ng/ml. The route of progesterone should be taken into consideration as the different routes of 406 
administration allow different serum concentrations of progesterone, for example, vaginal progesterone 407 
administration yields lower serum progesterone levels in comparison to intramuscular progesterone 408 
(Cicinelli and De Ziegler, 1999). Vaginal progesterone was given in all three studies suggesting that 409 
vaginal progesterone is able to replace endogenous progesterone from the corpus luteum at the levels 410 
of approximately 10-15 ng/ml in the artificial cycle.  In cases of suboptimal progesterone level, the 411 
decision of the day of embryo transfer would be changed to either the different day in the same cycle 412 
or defer to another cycle where the optimal progesterone levels are obtained. However, due to small 413 
sample size in our study, further larger studies investigating the effect of progesterone levels on both 414 
endometrial transcriptomics and pregnancy outcomes in multiple cycles for both natural and frozen-415 
thawed cycles are needed to confirm the predictive value of progesterone monitoring.  416 
Conclusion 417 
Suboptimal mid-luteal progesterone concentrations below 10-15 ng/ml are associated with aberrant 418 
expression of endometrial genes regulating processes such as extracellular matrix remodelling, 419 
decidualisation, and embryo-endometrial adhesion during the implantation window. Therefore, mid-420 
luteal progesterone monitoring might be useful to predict implantation potential, however, future 421 
clinical studies are needed to ensure its clinical benefit. 422 
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